The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
Level | Code | Title | |
---|---|---|---|
1 | L | Antineoplastic and immunomodulating agents | |
2 | L01 | Antineoplastic agents | |
3 | L01X | Other antineoplastic agents | |
4 | L01XA | Platinum compounds |
Code | Title | |
---|---|---|
L01XA01 | Cisplatin | |
L01XA02 | Carboplatin | |
L01XA03 | Oxaliplatin | |
L01XA04 | Satraplatin | |
L01XA05 |
Active Ingredient | Description | |
---|---|---|
Carboplatin |
Carboplatin interferes with DNA intrastrand and interstrand crosslinks in cells exposed to the drug. DNA reactivity has been correlated with cytotoxicity. |
|
Cis-Diaminedichloroplatinum |
Cisplatin is an anorganic substance containing a heavy metal [cis-diamminedichloroplatinum(II)]. This substance inhibits the DNA synthesis by realising transverse connections within and between the DNA strings. The protein and RNA synthesis is inhibited to a lesser extent. |
|
Oxaliplatin |
Oxaliplatin is an antineoplastic active substance belonging to a new class of platinum-based compounds in which the platinum atom is complexed with 1,2-diaminocyclohexane (“DACH”) and an oxalate group. |
|
Satraplatin |
Satraplatin is a cytotoxic agent. The primary cytotoxic mechanism of satraplatin is similar to that of other platinum compounds including cisplatin, carboplatin and oxaliplatin, and is based on the formation of DNA adducts. Platinum-DNA adducts, which are formed following uptake of the drug into the nucleus of the cell, activate several cellular processes that mediate the cytotoxicity of these drugs. These processes include the signalling of DNA damage, cell cycle checkpoints and arrest, DNA repair and cell death. |
Title | Information Source | Document Type | |
---|---|---|---|
CARBOPLATIN Solution for infusion | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
CISPLATIN Concentrate for solution for infusion | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
KEMOCARB Concentrate for solution for infusion | Health Sciences Authority (SG) | MPI, Generic | |
OXALIPLATIN Concentrate for solution | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |